Healthy cash position ($4.135m) with further cash injections namely R+D tax incentives for FY'17 & FY'18 (approx. $2.2m) ensures RGS is fully funded for operational activities, R+D and further clinical trials until FY'19.
Looks good!
Ann: Appendix 4C - Quarterly, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
